Clinical trial
Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and…
NCT00283621 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00283621 |
|---|---|
| Title | Aranesp and Neulasta in Patients With Sarcoma Receiving Adriamycin and Ifosfamide |
| Official title | A Pilot Study of Aranesp (Darbepoetin Alfa) and Pegfilgrastim (Neulasta) in Patients With Sarcoma Receiving Adriamycin and Ifosfamide |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide |
| Enrollment | 51 |
| Start date | Jun 2, 2003 |
| Primary completion | Apr 12, 2006 |
| Completion | Apr 12, 2006 |
| First posted | Jan 30, 2006 |
| Last update posted | Nov 7, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: